These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36366561)

  • 1. Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study.
    Conway A; Read P; Gilliver R; McNaughton T; Valerio H; Cunningham EB; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Grebely J
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
    Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
    Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
    Williams B; Howell J; Doyle J; Thompson AJ; Draper B; Layton C; Latham N; Bramwell F; Membrey D; Mcpherson M; Roney J; Stoové M; Hellard ME; Pedrana A
    Int J Drug Policy; 2019 Oct; 72():91-98. PubMed ID: 31129023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study.
    Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Dec; 110():103876. PubMed ID: 36240657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
    Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J;
    Int J Drug Policy; 2018 Nov; 61():23-30. PubMed ID: 30388566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.
    MacIsaac MB; Whitton B; Anderson J; Cogger S; Vella-Horne D; Penn M; Weeks A; Elmore K; Pemberton D; Winter RJ; Papaluca T; Howell J; Hellard M; Stoové M; Wilson D; Pedrana A; Doyle JS; Clark N; Holmes JA; Thompson AJ
    Int J Drug Policy; 2024 Mar; 125():104317. PubMed ID: 38281385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
    Howell J; Traeger MW; Williams B; Layton C; Doyle JS; Latham N; Draper B; Bramwell F; Membrey D; McPherson M; Roney J; Stoové M; Thompson AJ; Hellard ME; Pedrana A
    J Viral Hepat; 2022 May; 29(5):375-384. PubMed ID: 35274403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
    Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A
    Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study.
    Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J;
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland: A quantitative cross-sectional analysis.
    Yuan JM; Croxford S; Viviani L; Emanuel E; Phipps E; Desai M
    Int J Drug Policy; 2022 Nov; 109():103821. PubMed ID: 35994940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.
    Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L
    Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
    Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
    Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Setting foot in private spaces: extending the hepatitis C cascade of care to automatic needle/syringe dispensing machines, a mixed methods study.
    Coupland H; Henderson C; Pritchard-Jones J; Kao SC; Sheils S; Nagy R; O'Donnell M; Haber PS; Day CA
    Harm Reduct J; 2022 May; 19(1):56. PubMed ID: 35643528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California.
    Ozga JE; Syvertsen JL; Pollini RA
    J Viral Hepat; 2022 Jul; 29(7):518-528. PubMed ID: 35357738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark.
    Demant J; Krohn-Dehli L; Van der Veen J; Øvrehus A; Lazarus JV; Weis N
    Int J Drug Policy; 2023 Nov; 121():104185. PubMed ID: 37774576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
    Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
    J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.